P=N/A, N=9, Not yet recruiting, Children's Hospital of Fudan University

P2, N=8, Terminated, Dr. B. Catharine. Craven | Active, not recruiting --> Terminated; COVID-19 Pandemic

Furthermore, it predicted 51 candidate therapeutants, including atorvastatin, GSK-269962A, and atovaquone. These findings indicate that even in the absence of overt pathological stimulation, aortic tissue carrying the Myh11 K1256del variant exhibits a transcriptional program centered on ROCK signaling, which may prime the aorta for maladaptive responses to additional stress and may enhance susceptibility to dissection. This computational analysis requires experimental validation, but may provide a hypothesis-generating framework for development of preventive pharmacological interventions against FTAAD.

P=N/A, N=10000, Recruiting, JW Pharmaceutical

Notably, pitavastatin calcium synergized with the ferroptosis inducer RSL3 to enhance ferroptotic activity and suppress HNSCC progression. These findings delineate a TRAPPC4-FOS-TRIM55-GPX4 signaling axis that drives ferroptosis resistance and tumor progression and highlight TRAPPC4 as a promising therapeutic target for ferroptosis-based intervention in HNSCC.

P2/3, N=180, Recruiting, Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau | Not yet recruiting --> Recruiting

P2, N=456, Not yet recruiting, Beijing Inno Medicine Co., Ltd.

Our findings suggest that clinically significant OATP1B-mediated interactions are not anticipated with CDK4/6 inhibitors, either as victims or perpetrators, which supports ongoing clinical trials investigating the co-administration of CDK4/6 inhibitors with OATP1B substrates and inhibitors.

In vitro experiments confirmed the cytotoxicity and induction of methuosis in GBM cells by AP@CM-Ang, accompanied by the release of immune-stimulatory factors. In vivo experiments demonstrated that the nanodrug significantly enhanced tumor targeting, effectively inhibited tumor growth, and increased immune cell activation, validating its potential as a promising and safe strategy for GBM treatment.

A subcutaneous transplant tumor model was used to verify the inhibitory effect of fluvastatin (FLU) on NKTCL cells in vivo. Lastly, FLU and gemcitabine demonstrated satisfactory synergistic effects in tumor suppression and pyroptosis activation. Our data suggest that FLU represses NKTCL growth by promoting pyroptosis via the MVA-GGPP pathway.

P1, N=60, Not yet recruiting, International Vaccine Institute | Trial completion date: Mar 2026 --> Jul 2027 | Initiation date: Dec 2025 --> Jan 2027 | Trial primary completion date: Mar 2026 --> Jul 2027

P2/3, N=46, Not yet recruiting, Tanta University